

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2022/120136 A1

(43) International Publication Date
09 June 2022 (09.06.2022)

(51) International Patent Classification:

C07D 239/34 (2006.01) C07D 239/36 (2006.01)
C07C 255/46 (2006.01) C07D 401/14 (2006.01)
C07C 257/06 (2006.01) C07D 403/12 (2006.01)
C07C 257/16 (2006.01)

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/US2021/061754

(22) International Filing Date:

03 December 2021 (03.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/121,330 04 December 2020 (04.12.2020) US

(71) Applicant: **BLUEPRINT MEDICINES CORPORA-
TION** [US/US]; 45 Sidney Street, Cambridge, Massa-
chusetts 02139 (US).

(72) Inventors: **WAETZIG, Joshua**; c/o Blueprint Medicines
Corporation, 45 Sidney Street, Cambridge, Massachusetts
02139 (US). **WILKIE, Gordon D.**; c/o Blueprint Medi-
cines Corporation, 45 Sidney Street, Cambridge, Massachu-
setts 02139 (US). **PORAL, Vincent**; c/o Kadijk 3, 9747AT
Groningen (NL). **DROS, Albert Cornelis**; c/o Kadijk 3,
9747AT Groningen (NL).

(74) Agent: **KAVANAUGH, Theresa C.**; Goodwin Procter
LLP, 100 Northern Avenue, IP Docketing Dept/7th Floor,
Boston, Massachusetts 02210 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHOD OF PREPARING PRALSETINIB

(57) Abstract: Provided herein, in part, are compounds and compositions useful for preparing pralsetinib. Also provided herein are processes for preparing pralsetinib.

WO 2022/120136 A1